• World News
  • Politics
  • Stock
  • Investing
  • Editor’s Pick
Blue Chip Of Success
Politics

I need an expensive asthma drug to live. Trump’s RX plan helped me and many others

by February 20, 2026
by February 20, 2026

When President Donald Trump announced ‘TrumpRx’ in early February, a weight I’ve carried my entire adult life suddenly lifted from my shoulders. The website offers life-saving medications at much lower prices than normal, based on the president’s promise to give Americans the same prescription drug costs as patients in other developed countries. I can personally attest that such equal treatment — a policy known as ‘most favored nation’ pricing — is urgently needed for people who struggle with chronic disease.

I’ve had debilitating asthma since I was a child. I’ve been able to manage it thanks to a prescription drug which blocks lung inflammation and keeps my airways open. The few times I’ve gone off the medication, I’ve ended up in the emergency room, unable to breathe. That nearly happened four years ago in what I thought was the worst possible place — on the other side of the world, unable to contact my doctors or go to my pharmacy.

My family and I were in Italy, on a trip to honor my mother. She had recently been diagnosed with cancer and my brother and I scheduled the trip in between her chemo treatments, when she would be well enough to travel. She had always wanted to go there with us. But in our rush to get two families and three little kids packed, I accidentally grabbed a nearly empty inhaler.

I realized my mistake a few days into the trip, when I looked at the inhaler and saw that I only had two doses left. I wasn’t just worried about my health, though, of course, that was paramount. I worried how I’d afford the drug if I even found it in Italy.

I’ve organized my professional life around access to insurance that covers my medication, given its longstanding retail price $600 for a month’s supply. For 25 years, I’ve grappled with denied coverage letters, premium tier prescription charts and the constant worry that we would have to cut back on necessities to get my medication. At the time, in Italy, I was already paying a few hundred dollars a month for the drug — a lot, but a bargain compared to its normal price.

But I had no choice. I had to get my medication. After a few minutes of searching, I found an Italian pharmacy across town. I walked there immediately, trying to control my racing thoughts of what might happen. I knew that if I couldn’t get the drug, I couldn’t get safely back to the U.S.

Fifteen minutes later, in tears I walked out, drug in hand. It cost me only 30 euros or about $35.

At first, I was both relieved and grateful. But by the end of the day, I was scratching my head. Why was it $600 in the U.S. while Italians could get it for next to nothing? In the days that followed, I discovered that the answer is beyond complicated.

 GLP-1 drugs can be ‘too easy’ to get online, expert warns

It’s affected by everything from a lack of price transparency to the meddling of middlemen who jack up costs. It’s also true that foreign countries have been negotiating the prices of prescription drugs for decades, forcing Americans to cover the enormous cost of pharmaceutical development while they pay far below market prices.

Whatever the reason, the system doesn’t work for Americans. Brand name prescription prices in the U.S. are more than four times higher than prices in other wealthy countries. As many as 18 million Americans have struggled to buy the prescriptions they need in recent years.

I’m now using a generic version of the drug that costs significantly less. But that doesn’t change the fact that I, like many other Americans with chronic disease, have paid through the nose for decades on end, only to find the medication I needed in Italy for what seemed like pennies.

I wasn’t just worried about my health, though, of course, that was paramount. I worried how I’d afford the drug if I even found it in Italy.

0 comment
0
FacebookTwitterPinterestEmail

previous post
Aeris Integrates with Palo Alto Networks to Secure Wireless IoT Blind Spot
next post
Ex-Victoria’s Secret CEO’s lawyer caught on hot mic jokingly threatening to ‘kill’ him at Epstein deposition

You may also like

Ex-Victoria’s Secret CEO’s lawyer caught on hot mic...

February 20, 2026

What America’s most powerful warship brings to the...

February 20, 2026

Iran rebuilding nuclear program despite Trump talks, opposition...

February 20, 2026

Repeat offender labeled ‘danger to the community’ walks...

February 20, 2026

Trump’s NIH director isn’t the only official wearing...

February 20, 2026

UK blocks Trump from using RAF air bases...

February 20, 2026

Trump says Iran has 15 days to reach...

February 20, 2026

Cambodian PM says Thai forces occupying disputed land...

February 20, 2026

Built for weeks of war: Inside the firepower...

February 19, 2026

Rick Scott says Prince Andrew ‘absolutely’ must face...

February 19, 2026

Leave a Comment Cancel Reply

Save my name, email, and website in this browser for the next time I comment.

Join The Exclusive Subscription Today And Get Premium Articles For Free


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Recent Posts

  • What America’s most powerful warship brings to the Middle East as Iran tensions surge

    February 20, 2026
  • Ex-Victoria’s Secret CEO’s lawyer caught on hot mic jokingly threatening to ‘kill’ him at Epstein deposition

    February 20, 2026
  • I need an expensive asthma drug to live. Trump’s RX plan helped me and many others

    February 20, 2026
  • Aeris Integrates with Palo Alto Networks to Secure Wireless IoT Blind Spot

    February 20, 2026
  • Iran rebuilding nuclear program despite Trump talks, opposition figure claims

    February 20, 2026
  • About Us
  • Contacts
  • Email Whitelisting
  • Terms and Conditions
  • Privacy Policy

Copyright © 2023 BlueChipOfSuccess.com All Rights Reserved.

Blue Chip Of Success
  • World News
  • Politics
  • Stock
  • Investing
  • Editor’s Pick